Description
The presence of MET gene exon 14 loss serves as a predictor of response to MET inhibitor therapy in patients with locally advanced or metastatic non-small cell lung cancer. Determination of MET gene amplification is recommended for personalization of therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Period of execution
Within 11 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Tissue sample
- Tissue sample in paraffin block